PRTA
Prothena Corporation plc
Biotechnology
Market Cap$567M
5Y Perf.-1.2%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
PRTA vs DBVT vs REGN vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology
Market Cap$73.68B
5Y Perf.+15.7%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+6.1%
PRTA vs DBVT vs REGN vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PRTA | DBVT | REGN | IMVT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $567M | $1712.35T | $73.68B | $5.53B |
| Revenue (TTM) | $58M | $0.00 | $14.92B | $0.00 |
| Net Income (TTM) | $-151M | $-168M | $4.42B | $-464M |
| Gross Margin | -39.7% | — | 84.5% | — |
| Operating Margin | -210.6% | — | 24.3% | — |
| Forward P/E | 42.7x | — | 15.3x | — |
| Total Debt | $14M | $22M | $2.71B | $98K |
| Cash & Equiv. | $308M | $194M | $3.12B | $714M |
PRTA vs DBVT vs REGN vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PRTA
DBVT
REGN
IMVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Prothena Corporatio… (PRTA) | 100 | 98.8 | -1.2% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| Regeneron Pharmaceu… (REGN) | 100 | 115.7 | +15.7% |
| Immunovant, Inc. (IMVT) | 100 | 106.1 | +6.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRTA vs DBVT vs REGN vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: REGN leads in 6 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. DBV Technologies S.A. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PRTA
Prothena Corporation plc
The Defensive Pick
PRTA is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.96, Low D/E 4.9%, current ratio 7.72x
Best for: sleep-well-at-night
DBVT
DBV Technologies S.A.
The Momentum Pick
DBVT is the #2 pick in this set and the best alternative if momentum is your priority.
- +110.4% vs REGN's +27.1%
Best for: momentum
REGN
Regeneron Pharmaceuticals, Inc.
The Income Pick
REGN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.81, yield 0.5%
- Rev growth 1.0%, EPS growth 8.2%, 3Y rev CAGR 5.6%
- Beta 0.81, yield 0.5%, current ratio 4.13x
- 1.0% revenue growth vs DBVT's -100.0%
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 173.6% 10Y total return vs REGN's 90.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | REGN | 1.0% revenue growth vs DBVT's -100.0% |
| Value | REGN | Better valuation composite |
| Quality / Margins | REGN | 29.6% margin vs PRTA's -260.9% |
| Stability / Safety | REGN | Beta 0.81 vs IMVT's 1.37 |
| Dividends | REGN | 0.5% yield; 1-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs REGN's +27.1% |
| Efficiency (ROA) | REGN | 11.1% ROA vs DBVT's -89.0% |
PRTA vs DBVT vs REGN vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2025
Segment breakdown not available.
PRTA vs DBVT vs REGN vs IMVT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLREGNLAGGINGDBVT
Who Leads Where
REGN leads in 4 of 6 categories
IMVT leads 1 • PRTA leads 0 • DBVT leads 0 • 1 tied
Explore the data ↓DBVTDBV Technologies S.A.
0leads
PRTAProthena Corporation …
0leads
IMVTImmunovant, Inc.
1leads
REGNRegeneron Pharmaceuti…
4leads
6 Total Categories
CATEGORYLEADERvs IMVTvs PRTAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
REGN4/6
Valuation MetricsMultiples, price ratios, and targets
REGN2/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
REGN6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
REGN1/1
Income & Cash Flow (Last 12 Months)
REGN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
REGN and IMVT operate at a comparable scale, with $14.9B and $0 in trailing revenue. REGN is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to PRTA's -2.6%.
| Metric | PRTAProthena Corporat… | DBVTDBV Technologies … | REGNRegeneron Pharmac… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $58M | $0 | $14.9B | $0 |
| EBITDAEarnings before interest/tax | -$121M | -$112M | $4.2B | -$487M |
| Net IncomeAfter-tax profit | -$151M | -$168M | $4.4B | -$464M |
| Free Cash FlowCash after capex | -$85M | -$151M | $4.2B | -$423M |
| Gross MarginGross profit ÷ Revenue | -39.7% | — | +84.5% | — |
| Operating MarginEBIT ÷ Revenue | -2.1% | — | +24.3% | — |
| Net MarginNet income ÷ Revenue | -2.6% | — | +29.6% | — |
| FCF MarginFCF ÷ Revenue | -147.2% | — | +27.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +17.1% | — | +19.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +153.6% | +91.5% | -7.2% | +19.7% |
REGN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
REGN leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | PRTAProthena Corporat… | DBVTDBV Technologies … | REGNRegeneron Pharmac… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $567M | $1712.35T | $73.7B | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $273M | $1712.35T | $73.3B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -2.32x | -0.76x | 17.09x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | 42.68x | — | 15.35x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.70x | — |
| EV / EBITDAEnterprise value multiple | — | — | 17.78x | — |
| Price / SalesMarket cap ÷ Revenue | 58.54x | — | 5.14x | — |
| Price / BookPrice ÷ Book value/share | 2.02x | 0.66x | 2.46x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — | 18.06x | — |
REGN leads this category, winning 2 of 4 comparable metrics.
Profitability & Efficiency
REGN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
REGN delivers a 14.3% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-130 for DBVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), REGN scores 5/9 vs PRTA's 1/9, reflecting solid financial health.
| Metric | PRTAProthena Corporat… | DBVTDBV Technologies … | REGNRegeneron Pharmac… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -49.9% | -130.2% | +14.3% | -47.1% |
| ROA (TTM)Return on assets | -42.3% | -89.0% | +11.1% | -44.1% |
| ROICReturn on invested capital | -21.0% | — | +8.9% | — |
| ROCEReturn on capital employed | -47.0% | -145.7% | +10.2% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 5 | 2 |
| Debt / EquityFinancial leverage | 0.05x | 0.13x | 0.09x | 0.00x |
| Net DebtTotal debt minus cash | -$294M | -$172M | -$412M | -$714M |
| Cash & Equiv.Liquid assets | $308M | $194M | $3.1B | $714M |
| Total DebtShort + long-term debt | $14M | $22M | $2.7B | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x | 108.44x | — |
REGN leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs REGN's +27.1%. The 3-year compound annual growth rate (CAGR) favors IMVT at 12.1% vs PRTA's -48.5% — a key indicator of consistent wealth creation.
| Metric | PRTAProthena Corporat… | DBVTDBV Technologies … | REGNRegeneron Pharmac… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +14.5% | +4.9% | -8.5% | +5.1% |
| 1-Year ReturnPast 12 months | +44.4% | +110.4% | +27.1% | +96.1% |
| 3-Year ReturnCumulative with dividends | -86.3% | +19.7% | -5.1% | +40.9% |
| 5-Year ReturnCumulative with dividends | -57.2% | -69.1% | +43.6% | +62.4% |
| 10-Year ReturnCumulative with dividends | -73.0% | -87.0% | +90.0% | +173.6% |
| CAGR (3Y)Annualised 3-year return | -48.5% | +6.2% | -1.7% | +12.1% |
IMVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — REGN and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
REGN is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PRTAProthena Corporat… | DBVTDBV Technologies … | REGNRegeneron Pharmac… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.96x | 1.26x | 0.81x | 1.37x |
| 52-Week HighHighest price in past year | $11.69 | $26.18 | $821.11 | $30.09 |
| 52-Week LowLowest price in past year | $4.32 | $7.53 | $476.49 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +90.1% | +76.3% | +86.4% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 60.3 | 48.1 | 44.9 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 474K | 252K | 631K | 1.4M |
Evenly matched — REGN and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
REGN leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: PRTA as "Buy", DBVT as "Buy", REGN as "Buy", IMVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 22.1% for REGN (target: $866). REGN is the only dividend payer here at 0.48% yield — a key consideration for income-focused portfolios.
| Metric | PRTAProthena Corporat… | DBVTDBV Technologies … | REGNRegeneron Pharmac… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $19.00 | $46.33 | $865.68 | $45.50 |
| # AnalystsCovering analysts | 28 | 15 | 48 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.5% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 1 | — |
| Dividend / ShareAnnual DPS | — | — | $3.41 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +5.4% | 0.0% |
REGN leads this category, winning 1 of 1 comparable metric.
Key Takeaway
REGN leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). IMVT leads in 1 (Total Returns). 1 tied.
Best OverallRegeneron Pharmaceuticals, … (REGN)Leads 4 of 6 categories
Loading custom metrics...
PRTA vs DBVT vs REGN vs IMVT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PRTA or DBVT or REGN or IMVT a better buy right now?
For growth investors, Regeneron Pharmaceuticals, Inc.
(REGN) is the stronger pick with 1. 0% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Prothena Corporation plc (PRTA) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PRTA or DBVT or REGN or IMVT?
On forward P/E, Regeneron Pharmaceuticals, Inc.
is actually cheaper at 15. 3x.
03Which is the better long-term investment — PRTA or DBVT or REGN or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PRTA or DBVT or REGN or IMVT?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.
(REGN) is the lower-risk stock at 0. 81β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 71% more volatile than REGN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
05Which is growing faster — PRTA or DBVT or REGN or IMVT?
By revenue growth (latest reported year), Regeneron Pharmaceuticals, Inc.
(REGN) is pulling ahead at 1. 0% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Regeneron Pharmaceuticals, Inc. grew EPS 8. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PRTA or DBVT or REGN or IMVT?
Regeneron Pharmaceuticals, Inc.
(REGN) is the more profitable company, earning 31. 4% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PRTA or DBVT or REGN or IMVT more undervalued right now?
On forward earnings alone, Regeneron Pharmaceuticals, Inc.
(REGN) trades at 15. 3x forward P/E versus 42. 7x for Prothena Corporation plc — 27. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — PRTA or DBVT or REGN or IMVT?
In this comparison, REGN (0.
5% yield) pays a dividend. PRTA, DBVT, IMVT do not pay a meaningful dividend and should not be held primarily for income.
09Is PRTA or DBVT or REGN or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.
(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Both have compounded well over 10 years (REGN: +90. 0%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PRTA and DBVT and REGN and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PRTA is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; REGN is a mid-cap deep-value stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.